Tempest Therapeutics, Inc. (TPST) Deep Dive Video

Summary

A deeply discounted, post-pivot biotech: blockbuster-grade HCC survival data plus dual-target CAR‑T optionality—balanced by brutal Phase 3 and funding binaries.

View TPST stock page · Read the TPST research report

Loading the video player…